Enhertu was approved for both neoadjuvant and adjuvant treatment in patients with HER2-positive early breast cancer. The Food and Drug Administration (FDA) has expanded the approval of Enhertu ® ...
The TROP2-directed antibody-drug conjugate demonstrated superior efficacy over physician’s choice of chemotherapy in patients previously treated with platinum-based therapy and immunotherapy.
Two interchangeable golimumab biosimilars were approved for the treatment of rheumatoid arthritis and ulcerative colitis.
Modest but statistically significant reduction seen for women with placenta previa undergoing cesarean delivery.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results